|
| 36702174 | Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19. | Anaerobe | 2023 |
| 37039791 | Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. | JAMA | 2023 |
| 36124058 | Medication history-wide association studies for pharmacovigilance of pregnant patients. | Commun Med (Lond) | 2022 |
| 34394194 | Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. | Front Genet | 2021 |
| 31337270 | Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. | Annu Rev Pharmacol Toxicol | 2020 |
| 33033174 | Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study. | Mol Cancer Ther | 2020 |
| 32457445 | EHRs could clarify drug safety in pregnant people. | Nat Med | 2020 |
| 32428651 | Machine learning on drug-specific data to predict small molecule teratogenicity. | Reprod Toxicol | 2020 |
| 31769998 | Systematically Prioritizing Candidates in Genome-Based Drug Repurposing. | Assay Drug Dev Technol | 2019 |
| 29218624 | Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. | Target Oncol | 2018 |
| 29193979 | When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. | Assay Drug Dev Technol | 2017 |
| 28379727 | Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. | Assay Drug Dev Technol | 2017 |
| 25384256 | Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes. | ACS Chem Biol | 2015 |
| 21936578 | Phospholipase D: enzymology, functionality, and chemical modulation. | Chem Rev | 2011 |
| 20735042 | Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. | J Med Chem | 2010 |
| 19268584 | Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. | Bioorg Med Chem Lett | 2009 |
| 19299128 | Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. | Bioorg Med Chem Lett | 2009 |
| 17497509 | The ethical mouse: be not like Icarus. | Am J Bioeth | 2007 |
| 17085410 | Ethical considerations in the communication of unexpected information with clinical implications. | Am J Bioeth | 2006 |